UCB Unveils Groundbreaking Findings on BIMZELX for Hidradenitis Suppurativa at AAD 2026

In a significant development for patients suffering from moderate-to-severe hidradenitis suppurativa (HS), UCB, a global biopharmaceutical company, has presented new data on their medication, BIMZELX (bimekizumab-bkzx), at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This innovative treatment has demonstrated the potential for sustained symptom control over an impressive duration of three years.

Key Findings from the AAD Presentation

Research shared by UCB indicates that 86.1% of patients treated with BIMZELX were free from acute symptoms known as flares during the three-year follow-up, showcasing its durability and effectiveness. This finding is particularly important as flares can drastically impair the quality of life for HS patients, leading to significant physical and emotional distress.

Dr. Steven Daveluy from Wayne State University emphasizes the burden of HS, noting that over eighty percent of individuals experience monthly flares, complicating their daily lives. The data shared at AAD shows that nearly 90% of patients treated with BIMZELX had no exacerbations during their scheduled visits, positioning BIMZELX as a powerful option for long-term symptom management.

Importance of Early Treatment

Another poignant detail highlighted in UCB's analysis is the correlation between earlier treatment and better patient outcomes. Data suggest that individuals who begin BIMZELX therapy sooner—with less severe disease—experience better results at the three-year mark. Donatello Crocetta, UCB's Chief Medical Officer, remarked on the importance of timely diagnosis and intervention, stating that the findings reinforce a critical window of opportunity in managing HS effectively.

The comprehensive data emerged from the BE HEARD trials, which allowed for in-depth post hoc analyses. Among 367 patients who completed the extension study, results were impressive: 316 out of 367 participants maintained a flare-free status, validating BIMZELX’s efficacy across various patient demographics that included differing body mass indices, age brackets, disease weights, and severities.

Consistent Improvements Across Demographics

Further scrutiny revealed that efficacy improvements were consistent across different populations, with subgroups such as age and body mass index showing sustained responses throughout the treatment period. Notably, younger patients (<35 years) and those with shorter disease duration exhibited higher HiSCR response rates compared to older patients with longer disease history, reinforcing the idea that earlier intervention can significantly influence treatment success.

Conclusion

UCB's revelations at the AAD 2026 Annual Meeting set a promising tone for the HPC community and all stakeholders involved in the treatment of hidradenitis suppurativa. With the potential for sustained symptom control and improved life quality for patients, BIMZELX stands as a beacon of hope amid the challenges posed by this complex condition. As UCB continues its research endeavors, the focus remains on enhancing patient care and encouraging early therapeutic strategies.

These innovative findings highlight the ongoing commitment UCB holds to develop accessible and effective treatments, ensuring that those affected by hidradenitis suppurativa have the support and relief they desperately need.